DK2219665T3 - Parathyroidhormonformuleringer og anvendelse deraf - Google Patents

Parathyroidhormonformuleringer og anvendelse deraf

Info

Publication number
DK2219665T3
DK2219665T3 DK08842081.5T DK08842081T DK2219665T3 DK 2219665 T3 DK2219665 T3 DK 2219665T3 DK 08842081 T DK08842081 T DK 08842081T DK 2219665 T3 DK2219665 T3 DK 2219665T3
Authority
DK
Denmark
Prior art keywords
pth
parathyroid hormone
formulations
ionic surfactant
hormone formulations
Prior art date
Application number
DK08842081.5T
Other languages
English (en)
Inventor
Linderoth Dorte Loer
Hansen Lars Lindegaard
Original Assignee
Nycomed Danmark Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Danmark Aps filed Critical Nycomed Danmark Aps
Application granted granted Critical
Publication of DK2219665T3 publication Critical patent/DK2219665T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
DK08842081.5T 2007-10-26 2008-10-27 Parathyroidhormonformuleringer og anvendelse deraf DK2219665T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99606107P 2007-10-26 2007-10-26
EP07021017A EP2052736A1 (en) 2007-10-26 2007-10-26 Parathyroid hormone formulations und uses thereof
PCT/EP2008/009069 WO2009053106A1 (en) 2007-10-26 2008-10-27 Parathyroid hormone formulations and uses thereof

Publications (1)

Publication Number Publication Date
DK2219665T3 true DK2219665T3 (da) 2011-06-27

Family

ID=39146901

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08842081.5T DK2219665T3 (da) 2007-10-26 2008-10-27 Parathyroidhormonformuleringer og anvendelse deraf

Country Status (14)

Country Link
EP (2) EP2052736A1 (da)
AT (1) ATE501725T1 (da)
CY (1) CY1112106T1 (da)
DE (1) DE602008005643D1 (da)
DK (1) DK2219665T3 (da)
ES (1) ES2363272T3 (da)
HR (1) HRP20110444T1 (da)
MX (1) MX2010004388A (da)
PL (1) PL2219665T3 (da)
PT (1) PT2219665E (da)
RU (1) RU2467762C2 (da)
SI (1) SI2219665T1 (da)
WO (1) WO2009053106A1 (da)
ZA (1) ZA201002812B (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013027153A2 (pt) * 2011-04-22 2016-11-29 3M Innovative Properties Co método de aplicação de fármaco para pth, pthrp e peptídeos relacionados
CN103796666B (zh) * 2011-05-18 2018-07-06 欧莫德里斯制药公司 改良的肽药物
EP2785406A4 (en) 2011-11-30 2015-10-21 3M Innovative Properties Co MICRONADEL DEVICE WITH A PEPTIDE THERAPEUTIC AND AN AMINO ACID AND METHOD FOR THE PRODUCTION AND USE THEREOF
WO2014027281A1 (en) * 2012-08-13 2014-02-20 Koninklijke Philips N.V. Use of antioxidants in methods and means for detection of target molecules in a blood sample
FI3834824T3 (fi) 2014-03-28 2025-12-05 Univ Duke Estrogeenireseptoripositiivisen rintasyövän hoito selektiivisellä estrogeenireseptorin modulaattorilla
JP7019422B2 (ja) 2015-04-29 2022-02-15 ラジウス ファーマシューティカルズ，インコーポレイテッド 癌を治療するための方法
GB201602880D0 (en) 2016-02-18 2016-04-06 Ge Healthcare Uk Ltd Method and composition for biomolecule stabilization
MX2018009938A (es) 2016-03-01 2019-03-14 Ascendis Pharma Bone Diseases As Profarmacos de hormona paratiroidea (pth).
MA46428B1 (fr) 2016-09-29 2025-02-28 Ascendis Pharma Bone Diseases A/S Composés de pth à libération contrôlée
CN109789189B (zh) 2016-09-29 2024-01-23 阿森迪斯药物骨疾病股份有限公司 控释pth化合物的剂量方案
EP3518961B1 (en) 2016-09-29 2023-02-22 Ascendis Pharma Bone Diseases A/S Pth compounds with low peak-to-trough ratios
KR102707399B1 (ko) 2017-01-05 2024-09-13 래디어스 파마슈티컬스, 인코포레이티드 Rad1901-2hcl의 다형 형태
JP6577683B2 (ja) * 2017-09-22 2019-09-18 旭化成ファーマ株式会社 安定性に優れるテリパラチド含有液状医薬組成物
IL279853B2 (en) 2018-07-04 2025-01-01 Radius Pharmaceuticals Inc Polymorphic forms of RAD 1901-2HCL
JP7399382B2 (ja) * 2018-07-30 2023-12-18 武田薬品工業株式会社 組換えヒト副甲状腺ホルモンの安定性を向上させるための製剤
CA3129357A1 (en) * 2019-02-11 2020-08-20 Ascendis Pharma Bone Diseases A/S Liquid pharmaceutical formulations of pth conjugates
CN113348163B (zh) 2019-02-12 2024-10-08 雷迪厄斯制药公司 方法和化合物
CN112439054B (zh) * 2019-08-28 2023-05-16 深圳翰宇药业股份有限公司 一种特立帕肽缓释凝胶注射液及其制备方法
US20230190880A1 (en) * 2020-03-30 2023-06-22 Sichuan Luzhou Buchang Bio-Pharmaceutical Co., Ltd. Formulations of Human Parathyroid Hormone (PTH) and Methods for Producing Same
CN113101275A (zh) * 2021-05-27 2021-07-13 海南通用康力制药有限公司 注射用棓丙酯冻干粉针剂及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0643981B1 (en) * 1993-09-22 2002-01-09 Hisamitsu Pharmaceutical Co., Inc. A matrix for iontophoreses
ZA966075B (en) * 1995-07-27 1998-01-19 Genentech Inc Protein formulation.
KR101235507B1 (ko) * 2003-02-28 2013-02-20 추가이 세이야쿠 가부시키가이샤 단백질을 함유하는 안정화 제제
BRPI0416042A (pt) * 2003-11-13 2007-01-02 Alza Corp composição e aparelho para suprimento transdérmico
WO2007044375A2 (en) * 2005-10-06 2007-04-19 Nastech Pharmaceutical Company Inc. Pth formulations and methods of use
AU2006299887A1 (en) * 2005-10-06 2007-04-19 Nastech Pharmaceutical Company Inc. PTH formulations and methods of use
US8093207B2 (en) * 2005-12-09 2012-01-10 Unigene Laboratories, Inc. Fast-acting oral peptide pharmaceutical products

Also Published As

Publication number Publication date
ES2363272T3 (es) 2011-07-28
WO2009053106A1 (en) 2009-04-30
RU2467762C2 (ru) 2012-11-27
CY1112106T1 (el) 2015-11-04
DE602008005643D1 (de) 2011-04-28
RU2010121165A (ru) 2011-12-10
EP2219665A1 (en) 2010-08-25
MX2010004388A (es) 2010-08-10
ZA201002812B (en) 2011-12-28
HRP20110444T1 (hr) 2011-08-31
PT2219665E (pt) 2011-06-29
SI2219665T1 (sl) 2011-09-30
HK1146465A1 (en) 2011-06-10
PL2219665T3 (pl) 2011-11-30
EP2052736A1 (en) 2009-04-29
EP2219665B1 (en) 2011-03-16
ATE501725T1 (de) 2011-04-15

Similar Documents

Publication Publication Date Title
DK2219665T3 (da) Parathyroidhormonformuleringer og anvendelse deraf
BR112015023391A8 (pt) formulações de conjugados anticorpo-droga anti-egfr
EP4272731A3 (en) Compositions for the delivery of therapeutic agents and methods of use and making thereof
AR064614A1 (es) Producto combinado par controlar parasitos en animales
MX363023B (es) Formulaciones orales de analogos de citidina y metodos para usar los mismos.
MY167560A (en) Parasiticidal oral veterinary compositions comprising systemically-acting active agents, methods and uses thereof
GB2443287B (en) Methods, compositions and formulations for the treatment of thyroid eye disease
GT201000160A (es) Derivados de aminobenzamida como agentes útiles para el control de parásitos de animales
HRP20060147B1 (hr) Terapijski sustav s kontroliranim otpuštanjem za nazalnu primjenu
CO6311084A2 (es) Combinaciones de compuestos activos que tienen propiedades insecticidas y acaricidas
EP1981547A4 (en) STABLE THERAPEUTIC FORMULATIONS
MY161595A (en) Oral care compositions
MY163516A (en) Novel salts and polymorphs of desazadesferrithiocin polyether analogues as metal chelation agents
PH12012501620A1 (en) Oral care compositions
WO2011140232A3 (en) Desazadesferrothiocin and desazadesferrothiocin polyether analogues as metal chelation agents
EA201690323A1 (ru) Способы лечения заболеваний уха у детей
EP1993567A4 (en) PER OS ADMINISTRABLE GALLIUM PREPARATIONS AND METHODS OF USE
CO6280503A2 (es) Conjugados de neurturina novedosas para uso farmaceutico
EP4233915A3 (en) Modified release formulations of viloxazine
MX2007013327A (es) Formulaciones de liberacion prolongada.
CY1111361T1 (el) Νεα προσδεματα συναγωνιστες των υποδοχεων rar, χρηση στην ανθρωπινη ιατρικη καθως και στην κοσμετολογια
FR2894980B1 (fr) Compositions aqueuses epaissantes et limpides, leur utilisation dans des formulations aqueuses acides, formulations obtenues.
AR053804A1 (es) Composicion para controlar parasitos
AR069217A1 (es) Formulacion piojicida
TH166204A (th) " องค์ประกอบทางเภสัชกรรมเพื่อปลดปล่อยแลนรีโอไทด์ได้นานขึ้น (Pharmaceutical composition for a sustained release of lanreotide) "